Loading organizations...
§ Private Profile · Wellesley, MA, USA
A dermatology-focused biopharmaceutical company developing treatments for conditions like Acne Vulgaris and hyperhidrosis.
Atacama Therapeutics, Inc is a dermatology-focused biopharmaceutical company based in Wellesley Hills, Massachusetts, that develops targeted treatments for serious dermatological conditions presenting unmet clinical needs. The enterprise addresses complex patient ailments such as Acne Vulgaris and hyperhidrosis by executing rigorous proof-of-concept clinical trials for its emerging therapeutic pipeline. As part of its intellectual property strategy, the organization has filed one patent directly related to novel antiandrogen applications and specialized skin condition interventions. To finance these ongoing research initiatives, the firm has secured $830,000 in total venture capital funding across its investment rounds. The executive leadership team is guided by Series A board member David Dove and leverages prior life sciences exit experience, including the strategic acquisitions of Censa Pharmaceuticals by PTC and BioAssets by Cephalon. Atacama Therapeutics was founded in 2016 by biotechnology entrepreneurs Joseph Baron and Jonathan Reis.
Atacama Therapeutics, Inc has raised $2.0M across 1 funding round.
Atacama Therapeutics, Inc has raised $2.0M in total across 1 funding round.
Atacama Therapeutics, Inc has raised $2.0M in total across 1 funding round.
Atacama Therapeutics, Inc's investors include KittyHawk Ventures, Roy Peterkofsky.
Atacama Therapeutics, Inc has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Series A in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2023 | $2M Series A | — | KittyHawk Ventures, ROY Peterkofsky | Announced |
Atacama Therapeutics, Inc. is a dermatology-focused biopharmaceutical company developing treatments for serious skin conditions with significant unmet medical needs, such as Acne Vulgaris and palmar hyperhidrosis. Founded in 2016 and based in Wellesley Hills, Massachusetts, it targets proof-of-concept trials for novel therapies like AT-5214 (dexmecamylamine), a selective nicotinic acetylcholine receptor antagonist.[2][3][4][6] The company serves patients with moderate to severe dermatological disorders where few approved treatments exist, addressing gaps in efficacy and safety through rigorous clinical testing. It has raised $830K in unattributed funding about one year ago and remains active, with a pipeline centered on Phase 2 trials for hyperhidrosis.[3][4]
Atacama Therapeutics was founded in 2016 by a team of experienced life science professionals aiming to tackle serious dermatology conditions.[2][3] The idea emerged from identifying unmet needs in diseases like Acne Vulgaris—where regulatory approvals are scarce—and hyperhidrosis, prompting an initial focus on proof-of-concept trials for AT-5214.[2] Early traction included sponsoring two Phase 2 clinical trials: a completed exploratory study for TC-5214 in palmar hyperhidrosis starting December 2017 (NCT03404570), and another double-blind trial for AT-5214 starting January 2020.[4] Headquartered at 65 William Street, Suite 200, Wellesley Hills, MA, the company secured $830K in funding, marking pivotal early validation.[3][6]
Atacama Therapeutics rides the wave of precision dermatology and biopharma innovation, targeting antibiotic-resistant or hard-to-treat skin conditions amid rising demand for microbiome-preserving therapies.[1][2] Timing aligns with growing awareness of unmet needs in hyperhidrosis and acne, where traditional treatments fall short, fueled by market forces like increasing dermatology R&D investments and regulatory incentives for rare indications.[3][4] As a small, agile player in Massachusetts' biotech ecosystem, it contributes by advancing selective antagonists like dexmecamylamine, potentially influencing pipelines for sympathetic nervous system-targeted drugs and encouraging similar proof-of-concept models in underserved areas.[4]
Atacama's next milestones likely include advancing AT-5214 trial data toward Phase 3 or partnerships, leveraging its Phase 2 completion in hyperhidrosis to attract bigger funding or acquisitions.[3][4] Trends like AI-driven drug discovery and personalized dermatology will shape its path, amplifying small biotechs' impact through efficient trials. Its influence could grow by filling gaps in cholinergic-targeted therapies, evolving from niche developer to key innovator in dermatological unmet needs—reinforcing its role as a precise solver in a high-need therapeutic space.[2][4]